Building Health, Restoring Independence

Targacept is...

Targacept, Inc. is a biopharmaceutical company engaged in the development of novel NNR Therapeutics™ for the treatment of various diseases and disorders of the nervous system. Our NNR Therapeutics selectively target neuronal nicotinic receptors, or NNRs. NNRs are found on nerve cells throughout the nervous system and serve as key regulators of nervous system activity.

Focus on:

Our Culture

Targacept has assembled a dedicated team with years of experience in pharmaceutical development. READ MORE about our culture and aspirations.

Focus on:

Overactive Bladder 

Overactive bladder (OAB) poses a significant reduction in the quality of life for patients who suffer from the disorder.  READ MORE about our development plans for TC-5214 in this indication.



Targacept Homepage
Targacept, NNR Therapeutics, neuronal nicotinic receptors, NNR, neuronal nicotinic acetylcholine receptors, nicotinic acetylcholine receptors, nAChR, nicotinic, nicotinic agonist, nicotinic antagonist, nervous system disorders, psychiatric disorders, nicotinic channel modulator, central nervous system disorders, CNS, schizophrenia, residual phase schizophrenia, residual symptoms, negative symptoms, cognitive dysfunction, Alzheimer’s disease, age associated memory impairment, AAMI, mild cognitive impairment, MCI, cognition, Parkinson’s disease, L-dopa induced dyskinesia, alpha7 modulators, alpha4beta2 modulators, overactive bladder, OAB, TC-5619, TC-5214, TC-1734, AZD3480, AZD1446, TC-6987
Targacept is a biopharmaceutical company engaged in the development of novel NNR Therapeutics for the treatment of various diseases and disorders of the nervous system.